Investor Relations (IR) Questions: OncoGenex Pharmaceuticals OGXI
Click here to return to the biotech IRQ Index
Answers received: March 2013
1) When is the last time OGXI raised cash through an offering (diluted)?
OGXI last completed a financing in March 2012 that provided net cash of $53.8 million.
2) How much cash (not cash equivalents) does OGXI have?
OGXI had $75.4 million in cash, cash equivalents and short-term investments as of 12/31/12.
3) What and approximately when is the next known catalyst?
Next catalyst: data results expected to be announced H1 2014 for the custirsen Phase 3 SYNERGY trial in advanced prostate cancer.
4) What is OGXI's quarterly cash burn?
Net cash requirements for 2013 are expected to be in the range of $40 - $50 million.
5) Does OGXI have an existing line of credit and if so how much can they draw against it?
OGXI does not have an existing line of credit.
Also, click here for the complete BiotechDueDiligence OGXI stock research page and OncoGenex-related blog posts!
1) When is the last time OGXI raised cash through an offering (diluted)?
OGXI last completed a financing in March 2012 that provided net cash of $53.8 million.
2) How much cash (not cash equivalents) does OGXI have?
OGXI had $75.4 million in cash, cash equivalents and short-term investments as of 12/31/12.
3) What and approximately when is the next known catalyst?
Next catalyst: data results expected to be announced H1 2014 for the custirsen Phase 3 SYNERGY trial in advanced prostate cancer.
4) What is OGXI's quarterly cash burn?
Net cash requirements for 2013 are expected to be in the range of $40 - $50 million.
5) Does OGXI have an existing line of credit and if so how much can they draw against it?
OGXI does not have an existing line of credit.
Also, click here for the complete BiotechDueDiligence OGXI stock research page and OncoGenex-related blog posts!